This study applied meticulous experimentation involving HR+/HER2-low cell lines and animal models, highlighting the role of the HER2 pathway in the efficacy of CDK4/6 inhibitor combined with endocrine therapy for HR+/HER2-low breast cancer. The gene discussed is CDK4; the disease is breast carcinoma.